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Kazakhstan is an upper-middle-income country with per capita GDP of nearly 
US$13 thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified 
National Health System) – aims to deliver healthcare coverage to the whole popu-
lation. The political desire of authorities to provide broader access to healthcare 
for its populations, along with the growing prevalence of non-communicable dis-
eases (NCDs) such as cardiovascular disease, cancer and diabetes, are placing a 
strain not only on government budget but also on the healthcare infrastructure 
in Kazakhstan. Increasing life expectancy is giving rise to the greater burden 
associated with ageing populations, while governments struggle to balance grow-
ing costs with a need to expand healthcare provision to all. At the heart of any 
cost-containment strategy is a set of tools, ranging from complex risk-sharing 
schemes and health technology assessment (HTA) through to more simplistic 
mechanisms, such as prescribing controls and mandatory price cuts. Analysis of 
cost-management trends in Kazakhstan, relative with international experience, 
suggests a leaning towards less complex approaches. One reason for this is that 
before being able to even contemplate more sophisticated initiatives, governments 
must first address basic infrastructure needs. These include having sufficient doc-
tors and clinics to diagnose and treat patients. There is growing appreciation that 
cost containment can only be effective when implemented in a systematic man-
ner. Kazakhstan already have informal guidelines in place and are now consid-
ered «mature» markets in terms of HTA adoption. Despite the obvious challenges, 
some would argue that the time for HTA has arrived in Kazakhstan. Implemented 
correctly, it can play a role in the future of the region, not only as a key compo-
nent of cost containment but also as a pivotal enabler for the efficient use of 
resources, as governments look to provide broader access to affordable healthcare 
for all.
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Objectives: This conceptual paper aims to build a roadmap to reach integrated 
healthcare (HC) system in Egypt for optimum efficiency and utilization of resources 
among the different insurance bodies. The roadmap will help fill in the gaps 
evolved from the fragmented system having 5 different types of insurance cov-
erage. MethOds: Gap analysis between the desired integrated HC system that 
achieves; Equity, Solidarity and Free access to entire population, and the current 
situation of the HC system which was obtained from interviews and discussions 
with the HC payers and decision makers inside the public sector. Results: A 
ten year roadmap was built with eight action steps that were identified to reach 
integrated HC system: 1- Task Force Committee: from inside and outside the 
public sectors, 2- Research and Data centre: responsible for Epidemiological and 
Pharmacoepidemiological studies, 3- Prioritization plan: prioritize coverage plan 
based on budget and strategic diseases burden , 4- Treatment Protocols Flowchart: 
ensuring unified treatment guidelines across different HC bodies 5-Unique 
Patient ID: thus all insured patients are traceable without double counts, 6- Health 
Information System: connecting all HC units for optimum resources utilization, 
7- Primary Care Physicians Development Plan: continuous education programs 
for optimizing their utilization and freeing time to the over-utilized special-
ists, 8- Health Economics Unit: that will be the nucleus of establishing a Health 
Technology Assessment body responsible for economical strategic planning of the 
HC. RecOMMendAtiOns: Although some action steps were taken in some of the 
mentioned points however they were executed as separate initiatives inside the 
public sector; therefore it’s of high importance that the taskforce committee takes 
the accountability of executing the project as a single mission, and make sure the 
executed action steps are utilized and integrated with the rest of action steps as 
per the roadmap timetable.
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Objectives: The health care system reforms, which in many countries, par-
ticularly in the Eastern Europe, started in the 1990s, affected Latvia as well. The 
directions of the reforms can be divided into two basic segments – health care 
system organisation and health care system financing. Within the framework of 
this research, the author evaluates the health system research opportunities to 
assess the efficiency of the health care system reform in Latvia. MethOds: To 
achieve the goal of the research, the methods of the theoretical research are used 
alongside the methods of empirical research. The methods of statistical analy-
sis and methods of economic analysis are used for data processing and analy-
sis. Results: To perform the research, the author uses a three-level performance 
evaluation model based on macro-level evaluation, meso-level evaluation, and 
micro-level evaluation. The appropriate measures of the macro impact results, 
policy outcomes and performance outputs are defined to evaluate the effective-
ness of the performed health care system reform. The author assumes that the 
macro impact results are specified for public health, the policy outcomes are 
determined for the health care, as well as the pharmacy, while the performance’s 
outputs are representative for all areas. cOnclusiOns: The general conclusions 
show, for example, that the economic efficiency of the reimbursement system is 
sufficient and at the same time there is a tendency to move towards technical 
efficiency rather than total economic efficiency (technical and allocative effi-
ciency). The allocative efficiency in health economics is also associated with the 
market efficiency and effectiveness of the treatment process. However, the author 
notes that there are no perfect competition market conditions for health care 
products and services, so it is necessary to use alternative methods of economic 
analysis.
are completely damaged where others have been left with endangered to work in. 
The damaged infrastructure has left with inability to store essential drugs and vac-
cines. The cost of building new health care facilities is expected to reach billions of 
dollars. The cost required for the acute trauma is estimated very high. As homeless 
people are living in improper shelter, they have been presenting with other health 
related problems. For the short term relief, disaster management team should be 
formed in major government hospitals and medical colleges taking help of army and 
police health care personnel. Immediate enrolment of medical officers at the level 
of primary health centers should be done. A blend with major government and non-
government organizations like International Red Cross, United Nations Organization, 
World Health Organization, USAID etc. should be made to meet the health care equip-
ment, trained manpower and all other expenses. For the long term relief, trauma cent-
ers should be established in regional levels. As most of the remote villages even don’t 
have primary health centers, the health and sub health posts should be upgraded to 
meet the demands. Health posts and sub health posts should engage at least medical 
officers backed up by supportive staffs and basic investigations.
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bAckgROund: Market access for pharmaceuticals is evolving in a fast-changing 
environment : (1)Pressure of European Union (EU) Member States (MS) on health 
insurance budgets; (2) Dramatic technological advances; targeting new biological 
pathways, advanced therapy medicinal products, personalized medicines, expansion 
of digital medicine; (3) Initiatives from regulators and payers to develop synergies, 
e.g., collaborations between HTA agencies and multi-HTA/parallel early advice; (4) 
Increased payer risk-aversion and increasing products with limited information at 
launch; (5) Healthcare organisations moving towards integrated healthcare services 
(6) Ageing population and growing prevalence of chronic conditions, co-morbidi-
ties, and life threatening diseases; (7) Increased access inequity between EU MS. 
discussiOn: Cost-containment measures will increase under close supervision 
of parliaments. Fast development of electronic communication will allow online 
monitoring of drug utilisation. Adaptive licensing and limited evidence at time of 
launch will lead to generalization of coverage with evidence development. A more 
pragmatic approach in clinical trial designs should be considered to cope with con-
comitant development of companion diagnostics, segmentation of treated patients 
with targeted therapies; adaptive pathways should evolve from pilot to standard 
approach. Post-launch observational studies will become unavoidable to meet regu-
lators and payers’ expectations. Pan-European HTA coordination could lead to one 
single European HTA body assessing drugs prior to national HTA and pricing and 
reimbursement process. Managed entry agreements, ambulatory DRG, and bundled 
payments might become standard models. Integrated health services will expand, 
shifting payers role to health care providers. Differential pricing will address access 
inequity. cOnclusiOn: Sustainability of healthcare systems will remain at the 
heart of drug funding decisions. Drug market access will evolve through extended 
collaborations and interactions between key stakeholders. Drug licensing, pricing 
and reimbursement decisions will be increasingly coordinated to enable fast patient 
access to innovative therapies. Real-world data will be central to switch from initial 
restricted access to progressive wider coverage.
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bAckgROund: Adaptive pathways (AP) are prospective planned approaches to regula-
tion and coverage of drugs. Through iterative phases of evidence gathering, it aims to 
reduce uncertainties while balancing timely access for patients and level of available 
evidence. The concept assumes that all phases from development to clinical routine 
use through reimbursement are integrated. If AP did develop from regulatory per-
spective, many payers remain resistant. The aim of this research is to discuss payer’s 
position on AP. discussiOn: Payers show an increasing resistance to uncertainty and 
their decisions are mainly driven by evidence robustness. Regulators are integrating 
foregone alternative treatment opportunities in decision making and increasingly 
registering drugs with limited evidence and larger benefit estimates. Time from devel-
opment initiation to marketing authorization (MA) decreases overtime (compassionate 
use, accelerated assessment, conditional MA, MA under exceptional circumstances); 
On the opposite, time from MA to reimbursement expand with an increasing number 
of products denied reimbursement due to limited evidence. This gap between regula-
tors and payers continues to increase and AP may widen this gap. While managed 
entry agreements were thought to help managing uncertainty, it happens, in most of 
the cases, to be used as disguised cost-containment tools. Only coverage with evidence 
development (CED) with escrow agreements remain an appropriate tool to address 
uncertainty, but is rarely used. The difficulty to reverse reimbursement decision makes 
payers very sensitive to uncertainty. AP is unlikely to address the payers concern unless 
they are directly involved in identifying risk, designing mitigation plan, and moni-
toring the uncertainty. cOnclusiOn: AP may contribute to widen the gap between 
regulators and payers. Only CED with escrow agreement may be an appropriate tool 
to address payers’ uncertainty. However, AP pilot projects with expected high benefit 
will exercise pressure on payers to issue reimbursement.
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bAckgROund: mmunization decision-making (IDM) should draw on high qual-
ity evidence from various sources such as health economics (HE). Objective of 
this study was to test the applicability of a framework that enables a systematic, 
transparent, and evidence based IDM based on multiple criteria. MethOd: We 
applied the ‘Evidence to Decision (EtD) Framework’ developed by the ‘Developing 
and Evaluating Communication Strategies to Support Informed Decisions and 
Practice Based on Evidence’ (DECIDE) collaboration to the example of vaccination 
against pneumococcal-disease (PD) in adults and utilized HE evidence from a mod-
eling study for Germany. We tested how EtD criteria can be operationalized for the 
development of a specific IDM on which HE was expected to have a strong impact. 
A panel of members of the Methods-Working-Group of the German standing com-
mittee on vaccination (STIKO) was asked to use the EtD framework and judge on its 
applicability and usefulness for IDM. Results: Data from the HE model were used 
to inform one out of six criteria (disease-burden, evidence quality, magnitude of 
effects, balance of effects, cost-effectiveness, acceptability) of the EtD framework. 
Since two vaccine-types (23-valent polysaccharide and 13-valent conjugate vac-
cine [PPSV23, PCV13]) were compared in the HE model, judgement options for the 
HE criterion were: ‘favors PPSV23’; ‘favors PCV13’; ‘favors sequential vaccination 
PCV13&PPSV23’; ‘does not favor either’; ‘favors no vaccination’. Panel-members 
reported the usefulness of the EtD framework for IDM on PD vaccination, especially 
regarding the integration of HE result-figures. discussiOn: The EtD framework 
seems very suitable to consider HE in evidence based IDM even in a complex 
situation where multiple vaccination strategies are compared. It’s in particular 
helpful to communicate HE results-figures to non-economists and supports trans-
parency in IDM. In the project ‘Standardization of healTh Economic Evaluations 
of vaccINes in Germany’ (STEErING) the integration of HE in IDM will be further 
explored.
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Objectives: The objective of the present study was assess the impact of the 
performance evaluation, in terms of quality of the early warning indicators in 
Colombia during 2013 – 2014 between private and public IPS and the quantity of 
affiliates. The quality has been established as a key attribute in the comprehensive 
health care, which under the General System of Social Security in Health(SGSSS) 
in the Act100 of 1993 and the reforms of Decree1011 of 2006 and Resolution1446 
of the same year, was designed and implemented the policy of the system of 
warranties of quality in health care, in terms of quality of the early warning 
indicators(EWI). MethOds: A GLM and matching analysis comparing the quality 
in terms of timeliness and accessibility of health(TAH) care in the health insti-
tutions by department between 2013-2014 is proposed, taking into account the 
participation of affiliates in the contributory and subsidized regimen(CR-SR), in 
order to show that the number of members of the SGSSS at the departmental level 
is not necessarily determined by the increased presence of IPS or health centers 
or by the quality results of TAH. Results: The period studied, after running nine 
models of linear regression intertwined variables mentioned above (n_obs= 33), it 
was shown that members of the SR(SR”n2013= 22669543;n2014= 22882669”;&;CR”
n2013= 20150266;n2014= 20760123”)had a correlation of 30.63%compared to public 
regardless of private-IPS , while the worst correlation 7.54 %was manifested in 
the SRmembers attending Pr-IPS, since a high degree of omitted variables Pu-Pr-
IPS manifests48.66%. cOnclusiOns: SR had a notable effect over the quantity 
of affiliates in the health system. Affiliates of both Regimens prefer to assist to 
pu-IPS considering that had the highest quality(EWI). This research will open the 
discussion about the relevance of quality indicators in health and their relation 
with national budget, and what will happen if Colombia implement a Universal 
Health System.
dISeASe – SPeCIfIC StudIeS
InfeCtIon – Clinical outcomes Studies
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PrevAlenCe of HePAtItIS C And PreSenCe of ComorBIdItIeS In Sweden: 
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Objectives: The aim of the study was to estimate the prevalence of chronic hepati-
tis C (CHC) using Swedish nationwide register data. The secondary objective was to 
describe the presence of comorbidities compared with matched general population 
controls. MethOds: Patients were identified according to international classifica-
tion codes (ICD) for hepatitis C (HCV) in inpatient care (1987–2013), day surgery and 
non-primary outpatient care (1997–2013) in the nationwide Swedish Patient Register. 
The prevalence of CHC was defined as cumulative prevalence, and calculated as 
the number of patients alive and resident in Sweden Dec 31st 2013 with a diagnosis 
listings for CHC during the study period divided by the total Swedish population 
on that date (n= 9 644 864). Five general population controls were matched by age, 
sex, and county of residence to each CHC patient. Presence of co-morbidities were 
ascertained from the same register after CHC diagnosis and compared with matched 
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In 2010, the Ministry of Health (MoH) requested USAID for technical assis-
tance to implement interventions to improve the HIV/AIDS supply chain sys-
tem. Assessments revealed that fragmentation of the pharmaceutical system 
contributed to stock-outs and expiration of antiretroviral (ARVs) and other 
medicines and supplies used by disease control programs (DCPs). The imple-
mentation of an integrated system was proposed as the most efficient and sus-
tainable alternative to confront the HIV/AID pharmaceutical supply problems. 
Since 2011, the MoH with the support of USAID partners is integrating vertical 
DCP systems –including Tuberculosis and HIV/AIDS- into a single pharmaceuti-
cal management system (SUGEMI, in Spanish). The implementation of SUGEMI 
included: (1) an evidence-based for the design of the system and implemen-
tation of particular interventions; (2) institutional strengthening of national 
and regional implementing units; (3) legal support through Ministry and 
Presidential Decrees; (4) development and implementation of standard operating 
procedures (SOPs). Since 2014, the HIV/AIDS program has moved the ARVs from 
program specific stores to integrated warehouses; their personnel is using stand-
ardized SUGEMI formularies for requisition and delivery; and, has participated in 
national forecasting exercises leading to the procurement of quantities of ARVs, 
closer to the estimated needs of the patients. As a result of these interventions in 
2014 and 2015, the availability of ARVs has increased from 40% to a 97% in health 
facilities and 70% to a 100% in central warehouse. Simultaneous interventions in 
various pharmaceutical management components, within an integrated national 
pharmaceutical system have contributed to increase the availability of ARVs in 
the Dominican public health system.
PHP352
HeAltH teCHnology ASSeSSment PrACtICeS In turkey
Demirbas AR1, Oner N1, Beyan A1, Sener O1, Turgut CG2
1General Directorate of Health Research, Ankara, Turkey, 2Johnson & Johnson, Istanbul, Turkey
The Ministry of Health of Turkey has a system that places a high value on improv-
ing health care in all areas. The Ministry has initiated a project called “Health 
Transition” which has some sub-components to provide the above-mentioned 
goal . A number of national priorities have been established for these components 
one of which is to address health technology assessment (HTA). Health technology 
covers a variety of practices including pharmaceuticals, medical devices, surgical 
methods and health systems that are used for protecting and promoting health; 
and preventing, diagnosing and curing of diseases. Health Economics and in par-
ticular HTA is also a high priority for the European Union (EU) as stated in the 15th 
article of the directive 2011/24/EU related to the application of patients’ rights in 
cross-border health care. Despite HTA being a high-value speciality, the Turkish 
health care system has just newly developed its HTA perspective. Even though 
the system has been put in place recently and somehow fragmented between dif-
ferent institutions, HTA department in Turkey has conducted some research and 
reports regarding medical devices and pharmaceuticals some of which have not 
yet been concluded. It is also an active member of European Health Technology 
Assessment Network by having roles and responsibilities in working packages and 
authorship in projects. There is however a long way to go. In this paper, current 
situation of Turkish Health Technology Assessment capacity has been discussed 
and some information has been given regarding the efforts of cohesion between 
EU and international society.
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Objectives: Cost-effectiveness evaluations of new products are currently entirely 
focused on incremental cost-effectiveness ratios (ICERs) calculated over the stand-
ard of care (SoCs), and do not take into consideration the cost-effectiveness inher-
ent/implicit of the SoCs themselves. We argue that the average cost-effectiveness 
of the SoC, expressed as a ratio of the difference in costs between the SoC and no 
treatment/best supportive care (NT/BSC), to the difference in outcomes, or the 
ACER, also merits regular evaluation to enable comparison of value being derived 
from healthcare spend across indications. MethOds: To compute ACERs of SoCs, 
the costs associated with the SoC, and the benefits accrued were compared with 
that of NT/BSC applicable to each indication, based on inputs derived from previ-
ously accepted NICE evaluations. This exercise was carried out over 25 different 
indications spread across cancers, endocrine disorders, infectious diseases and 
immune disorders. Results: ACERs varied considerably, from a low of £717 (influ-
enza in elderly) to the high seen in Prader-Willi syndrome of £148,675 with a mean 
of £33,700 and median of £27,190. ACERs in endocrinology ranged from £25,485 to 
£148,675, oncology from £9,367 to £38,641; infectious diseases from £717 to £13,710, 
and immune disorders from £22,728 to £90,156. discussiOn: Evaluation of reign-
ing ACERs of the SoCs in different indications helps in: a) getting an estimate of 
the economic value of the healthcare budget being spent in particular indications, 
and across the pharmaceutical product spectrum, b) calibrating and evaluating 
currently accepted threshold ICERs; and c) providing decision-makers with data 
that encourages them to consider permitting greater leeway for new products’ 
ICER acceptability in indications where the SOC’s ICER may be at the lower end 
of the range, and conversely, to tighten limits in indications where the current 
SoC’s ACER may be at the higher end of the range, and thereby narrowing the 
range.
